title: Opioid receptor heteromers in analgesia.
abstract: Opiates such as morphine and fentanyl, a major class of analgesics used in the clinical management of pain, exert their effects through the activation of opioid receptors. Opioids are among the most commonly prescribed and frequently abused drugs in the USA; however, the prolonged use of opiates often leads to the development of tolerance and addiction. Although blockade of opioid receptors with antagonists such as naltrexone and naloxone can lessen addictive impulses and facilitate recovery from overdose, systemic disruption of endogenous opioid receptor signalling through the use of these antagonistic drugs can have severe side effects. In the light of these challenges, current efforts have focused on identifying new therapeutic targets that selectively and specifically modulate opioid receptor signalling and function so as to achieve analgesia without the adverse effects associated with chronic opiate use. We have previously reported that opioid receptors interact with each other to form heteromeric complexes and that these interactions affect morphine signalling. Since chronic morphine administration leads to an enhanced level of these heteromers, these opioid receptor heteromeric complexes represent novel therapeutic targets for the treatment of pain and opiate addiction. In this review, we discuss the role of heteromeric opioid receptor complexes with a focus on mu opioid receptor (MOR) and delta opioid receptor (DOR) heteromers. We also highlight the evidence for altered pharmacological properties of opioid ligands and changes in ligand function resulting from the heteromer formation.
authors.affiliation: Department of Pharmacology and Systems Therapeutics, The Friedman Brain Institute, Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: Cristina M
authors.initials: CM
authors.lastname: Costantino
authors.forename: Ivone
authors.initials: I
authors.lastname: Gomes
authors.forename: Steven D
authors.initials: SD
authors.lastname: Stockton
authors.forename: Maribel P
authors.initials: MP
authors.lastname: Lim
authors.forename: Lakshmi A
authors.initials: LA
authors.lastname: Devi
mesh_terms: D000698:Analgesia; D000700:Analgesics; D000818:Animals; D004336:Drug Antagonism; D062787:Drug Overdose; D006801:Humans; D009021:Morphine Dependence / Q000188:drug therapy / Q000378:metabolism; D009270:Naloxone / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D009271:Naltrexone / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy / Q000378:metabolism; D055503:Protein Multimerization / Q000187:drug effects*; D020836:Protein Structure, Quaternary; D017465:Receptors, Opioid, delta / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014481:United States
chemical_list: D000700:Analgesics; D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D009270:Naloxone; D009271:Naltrexone